| Clinical Trial |
Vaccine |
Sponsor |
Location |
Principal Objective |
Start
Date |
End Date |
Projected
Enrollees |
Notes |
| NCT01047839 |
IC51 |
Intercell AG |
USA, Australia,
Denmark,
Germany,
Sweden |
Determine safety and immunogenicity
in children |
Jan. 2010 |
Nov.
2011 |
100 |
Vaccine also marketed as
IXIARO® or JESPECT® |
| NCT01092507 |
JE-CV |
Sanofi-Aventis |
Thailand |
Demonstrate non-inferiority of one
dose of JE-CV compared to one dose
of live-attenuated SA14-14-2 |
Mar.
2010 |
Oct. 2015 |
300 |
Includes long-term follow-up
studies out to 5 years post
vaccination |
| NCT01158599 |
IC51 |
Intercell AG |
Austria,
Germany |
Determine safety and immunogenicity
in the elderly |
Jun-10 |
Jun-11 |
200 |
Vaccine also marketed as
IXIARO® or JESPECT®; |
| NCT01190228 |
JE-CV |
Sanofi-Aventis |
Philippines |
Determine safety and immunogenicity
of one dose of JE-CV; evaluate
severe adverse events for 5 years |
Aug.
2010 |
May-16 |
505 |
Immunogenicity also followed to 5
years post-vaccination |
| NCT01188343 |
JE-CV |
Sanofi-Aventis |
Taiwan |
Compare immunogenicity of JE-CV
alone or when given in combination
with measles-mumps-rubella vaccine |
Aug.
2010 |
Jan.
2012 |
550 |
Separate and co-immunization of
JE-CV and MMR; children 12-18
mo.; |
| NCT01150942 |
KD-287 |
Boryung
Pharma. |
Korea |
Assess safety and immunogenicity
of inactiveted JE vaccine in children
aged 12-23 mo. |
Aug.
2010 |
Aug.
2012 |
188 |
Three dose vaccine regimen |
| NCT01335412 |
IC51 |
Intercell AG |
USA-Virginia |
Surveillance for serious adverse
events in active military personnel
vaccinated with XIARO |
Mar.
2011 |
N/A |
20,000 |
Electronic surveillance program for
all vaccinated military personnel;
no enrollment |
